Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Genetically engineered attenuated herpes simplex viruses.

B Meignier1

  • 1Pasteur Mérieux Sérums et Vaccins, Marcy L'Etoile, France.

Reviews of Infectious Diseases
|November 1, 1991
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Characterization of Vero cell growth and death in bioreactor with serum-containing and serum-free media.

Cytotechnology·2008
Same author

Industrial experience with live polio vaccine prepared on the Vero continuous cell line.

Developments in biologicals·2002
Same author

Safety and immunogenicity of a live recombinant canarypox virus expressing HIV type 1 gp120 MN MN tm/gag/protease LAI (ALVAC-HIV, vCP205) followed by a p24E-V3 MN synthetic peptide (CLTB-36) administered in healthy volunteers at low risk for HIV infection. AGIS Group and L'Agence Nationale de Recherches sur Le Sida.

AIDS research and human retroviruses·1999
Same author

Canarypox virus-based vaccines: prime-boost strategies to induce cell-mediated and humoral immunity against HIV.

AIDS research and human retroviruses·1998
Same author

Fine specificity of anti-V3 antibodies induced in chimpanzees by HIV candidate vaccines.

AIDS research and human retroviruses·1998
Same author

Restricted specificity of anti-V3 antibodies induced in humans by HIV candidate vaccines.

AIDS research and human retroviruses·1997
Same journal

Fatal necrotizing otitis externa in a patient with AIDS.

Reviews of infectious diseases·1991
Same journal

Use of the polymerase chain reaction for the specific and direct detection of Clostridium difficile in human feces.

Reviews of infectious diseases·1991
Same journal

A new case of meningitis due to Pasteurella multocida.

Reviews of infectious diseases·1991
Same journal

Disseminated pelvic actinomycosis presenting as metastatic carcinoma: association with the progestasert intrauterine device.

Reviews of infectious diseases·1991
Same journal

Role of altered drug metabolism in virus-drug interactions.

Reviews of infectious diseases·1991
Same journal

Anaerobic bacteremia: declining rate over a 15-year period.

Reviews of infectious diseases·1991
See all related articles

Two new herpes simplex virus vaccines (R7020 and R7017) show promise. They are genetically stable, prevent severe disease and latency, and are safe in non-human primates.

Area of Science:

  • Virology
  • Vaccinology
  • Immunology

Background:

  • Herpes simplex virus (HSV) infections are a global health concern.
  • Current treatments are palliative, highlighting the need for effective vaccines.
  • Recombinant viral vectors offer a promising strategy for vaccine development.

Purpose of the Study:

  • To construct and evaluate novel recombinant herpes simplex viruses (HSVs) as potential vaccines.
  • To assess the genetic stability, latency, and protective efficacy of these recombinants.
  • To determine the safety and behavior of a lead candidate (R7020) in a non-human primate model.

Main Methods:

  • Construction of two recombinant HSV-1 vectors (R7020 and R7017) with deletions and duplicated glycoprotein genes (gD, gG, gE).
  • Evaluation of genetic stability, latency, and protection against HSV disease in rodent models.

Related Experiment Videos

  • Assessment of R7020 replication, dissemination, reactivation, and lesion development in Aotus monkeys, including under immunosuppression.

    • Main Results:

    • Both R7020 and R7017 demonstrated genetic stability and ability to establish latency in rodents.
    • The recombinant viruses provided significant protection against severe herpetic disease and prevented latency establishment.
    • In Aotus monkeys, R7020 replicated locally, did not disseminate, and reactivated without causing lesions, even when immunosuppressed.

    Conclusions:

    • Recombinant HSV vectors R7020 and R7017 are genetically stable and demonstrate potent protective efficacy against HSV disease and latency in preclinical models.
    • R7020 exhibits a favorable safety profile in Aotus monkeys, with controlled replication and asymptomatic reactivation.
    • These findings support the further development of these recombinant HSV vectors as potential vaccines against herpes simplex virus infections.